BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 36088510)

  • 1. Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients.
    Keup C; Suryaprakash V; Storbeck M; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Cells; 2021 Jan; 10(2):. PubMed ID: 33494385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
    Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
    Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
    [No Abstract]   [Full Text] [Related]  

  • 3. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
    Paoletti C; Cani AK; Larios JM; Hovelson DH; Aung K; Darga EP; Cannell EM; Baratta PJ; Liu CJ; Chu D; Yazdani M; Blevins AR; Sero V; Tokudome N; Thomas DG; Gersch C; Schott AF; Wu YM; Lonigro R; Robinson DR; Chinnaiyan AM; Bischoff FZ; Johnson MD; Park BH; Hayes DF; Rae JM; Tomlins SA
    Cancer Res; 2018 Feb; 78(4):1110-1122. PubMed ID: 29233927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
    Kim MH; Kim GM; Ahn JM; Ryu WJ; Kim SG; Kim JH; Kim TY; Han HJ; Kim JY; Park HS; Park S; Park BW; Kim SI; Jeong J; Lee J; Paik S; Kim S; Jung KH; Cho EH; Sohn J
    J Natl Cancer Inst; 2023 Sep; 115(9):1036-1049. PubMed ID: 37166557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dynamic range of circulating tumor DNA in metastatic breast cancer.
    Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
    Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection.
    Liu HE; Triboulet M; Zia A; Vuppalapaty M; Kidess-Sigal E; Coller J; Natu VS; Shokoohi V; Che J; Renier C; Chan NH; Hanft VR; Jeffrey SS; Sollier-Christen E
    NPJ Genom Med; 2017; 2():34. PubMed ID: 29263843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-based monitoring identifies acquired and targetable driver
    Medford AJ; Dubash TD; Juric D; Spring L; Niemierko A; Vidula N; Peppercorn J; Isakoff S; Reeves BA; LiCausi JA; Wesley B; Malvarosa G; Yuen M; Wittner BS; Lawrence MS; Iafrate AJ; Ellisen L; Moy B; Toner M; Maheswaran S; Haber DA; Bardia A
    NPJ Precis Oncol; 2019; 3():18. PubMed ID: 31341951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
    Corné J; Quillien V; Godey F; Cherel M; Cochet A; Le Du F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; De la Motte Rouge T
    Mol Oncol; 2024 Jan; ():. PubMed ID: 38287892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic changes in tumor profiling reveal intra- and inter-tumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient.
    Schaffrin-Nabe D; Josten-Nabe A; Tannapfel A; Uhl W; Garmer M; Kurzrock R; Crook T; Limaye S; Schuster S; Patil D; Schaffrin M; Mokbel K; Voigtmann R
    Front Oncol; 2024; 14():1395618. PubMed ID: 38764581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic progression of breast cancer along with decreased mitochondrial cell death priming of breast cancer cells: a case report.
    Aka Y; Ozdemir H; Torun N; Bolat FA; Kutuk O
    Oxf Med Case Reports; 2024 Mar; 2024(3):omae014. PubMed ID: 38532756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.
    Qin Y; Huo M; Liu X; Li SC
    Front Immunol; 2024; 15():1368749. PubMed ID: 38524135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onco-Breastomics: An Eco-Evo-Devo Holistic Approach.
    Neagu AN; Whitham D; Bruno P; Arshad A; Seymour L; Morrissiey H; Hukovic AI; Darie CC
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
    Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
    Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
    Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
    Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA.
    Allsopp RC; Page K; Ambasager B; Wadsley MK; Acheampong E; Ntereke TP; Guo Q; Lall GM; Gleason KLT; Wren E; Nteliopoulos G; Rushton AJ; Coombes RC; Shaw JA
    Clin Chem; 2023 Apr; 69(5):510-518. PubMed ID: 36747279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid biopsy: current technology and clinical applications.
    Nikanjam M; Kato S; Kurzrock R
    J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.